Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fuzheng Huayu and Entecavir in HBV-related Cirrhosis
NCT02241616Phase 4Unknown
- Sponsor
- Shuguang Hospital
- Start
- Sep 2014
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of fuzheng huayu in Liver Fibrosis (LF) and Liver cirrhosis (LC), sponsored by Shuguang Hospital. Primary endpoint: Degree of liver fibrosis at 48 weeks. Status: unknown.
02
Drugs
fuzheng huayu
03
Conditions
Liver Fibrosis (LF)Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT02241616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02241616.